Foster Wheeler says its Global Engineering and Construction Group has been awarded by KEDRION GROUP and its Hungarian-controlled HUMAN BIOPLAZMA LLC. a contract for engineering, procurement, construction management and commissioning/qualification supervision for the upgrading and expansion of a bulk plasma fractionation manufacturing facility at Gödöllö, Hungary.

KEDRION is a biopharmaceutical company specializing in the development, manufacture and distribution of plasma-derived medicinal products.

The Foster Wheeler contract value for this project was not disclosed and was included in the company’s second-quarter 2009 bookings.

The contract consists of the upgrading and capacity expansion of an existing plasma fractionation plant in line with Good Manufacturing Practice (GMP), including the installation of a new production line. During the upgrading works, the existing line will remain in operation. The plant is expected to be completed in the first quarter of 2011.

“We are very pleased to assign the execution of such an important project to Foster Wheeler,” said Rodolfo Franceschini, global operations director of KEDRION GROUP. “The strong cooperation between Foster Wheeler and KEDRION GROUP has been developing as a real partnership, aimed to get the target.”

Tags: Foster Wheeler Ltd.